SEC 13F Intelligence

Managers / Q4 2022 · view latest →

M28 Capital Management LP

CIK 0001807489 · 700 CANAL STREET, 1ST FLOOR, STAMFORD, CT, 06902 · 203-516-3730

Reported Value
$105M
Q4 2022
Positions
14
Filings on Record
18
2019–present window
Filed
Feb 10, 2023
original filing

Summary

M28 Capital Management LP reported $105M in U.S.-listed holdings across 14 positions for Q4 2022.

The portfolio is heavily concentrated: WVE alone accounts for 39.4% of reported value.

Compared with Q3 2022, the fund opened 5 new positions and exited 3.

Portfolio Metrics

Turnover
+30.2%
vs prior filed quarter
Top-10 Concentration
+95.3%
share of reported value
Largest Position
+39.4%
Wave Life Sciences
New / Exited
5 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $128MQ4 ’21Q1 ’22: $109MQ2 ’22: $89MQ3 ’22: $96MQ3 ’22Q4 ’22: $105MQ1 ’23: $88MQ2 ’23: $76MQ2 ’23Q3 ’23: $87MQ4 ’23: $121MQ1 ’24: $135MQ1 ’24Q2 ’24: $77MQ3 ’24: $91MQ4 ’24: $102MQ4 ’24Q1 ’25: $73MQ2 ’25: $59MQ3 ’25: $68MQ3 ’25Q4 ’25: $138MQ1 ’26: $54Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 88.8%Other: 9.1%ADR: 2.1%
  • Common Stock · 88.8% · $93M
  • Other · 9.1% · $10M
  • ADR · 2.1% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ARWRARROWHEAD PHARMACEUTICALS INNEW+143.9K143.9K+$6M$6M
IONSIONIS PHARMACEUTICALS INCNEW+126.3K126.3K+$5M$5M
SPRINGWORKS THERAPEUTICS INCNEW+109.9K109.9K+$3M$3M
SLNSILENCE THERAPEUTICS PLCNEW+145.9K145.9K+$2M$2M
ATARA BIOTHERAPEUTICS INCNEW+439.3K439.3K+$1M$1M
MIRATI THERAPEUTICS INCSOLD OUT−61.2K0−$4M$0
VERVE THERAPEUTICS INCSOLD OUT−87.6K0−$3M$0
LEAP THERAPEUTICS INCSOLD OUT−2.66M0−$2M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

14 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1WVEWAVE LIFE SCIENCES LTDhistory →SHS39.39%$41M5.90M
2RCKTROCKET PHARMACEUTICALS INChistory →COM13.47%$14M722.1K
3IVVDINVIVYD INChistory →COM13.22%$14M9.25M
4PROQR THRAPEUTICS N VSHS EURO6.74%$7M1.91M
5ARWRARROWHEAD PHARMACEUTICALS INhistory →COM5.56%$6M143.9K
6IONSIONIS PHARMACEUTICALS INChistory →COM4.55%$5M126.3K
7STOKSTOKE THERAPEUTICS INChistory →COM4.25%$4M482.9K
8BBIOBRIDGEBIO PHARMA INChistory →COM3.04%$3M419.0K
9SPRINGWORKS THERAPEUTICS INCCOM2.72%$3M109.9K
10CURIS INCCOM NEW2.35%$2M4.48M
11SLNSILENCE THERAPEUTICS PLChistory →ADS2.12%$2M145.9K
12ATARA BIOTHERAPEUTICS INCCOM1.37%$1M439.3K
13TGTXTG THERAPEUTICS INChistory →COM1.18%$1M104.4K
14NEXIMMUNE INCCOM0.03%$32,440133.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$54M9May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$138M9Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$68M9Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$59M9Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$73M11May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$102M11Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$91M11Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$77M11Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$135M11May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$121M10Feb 12, 202413F-HRchanges · EDGAR ↗
Q3 2023$87M11Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$76M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$88M14May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M14Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$96M12Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$89M13Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$109M13May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$128M12Feb 11, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.